The abnormal cerebrospinal fluid levels of biomarkers, such as β‐amyloid and phosphorylated tau (pTau), support the biological diagnosis of Alzheimer Disease (AD) independently of its clinical stage. However, this invasive… Click to show full abstract
The abnormal cerebrospinal fluid levels of biomarkers, such as β‐amyloid and phosphorylated tau (pTau), support the biological diagnosis of Alzheimer Disease (AD) independently of its clinical stage. However, this invasive exam cannot be extensively applied and requires previous sound clinical screen that can be based on brief, well validated cognitive tests, such as the Phototest.
               
Click one of the above tabs to view related content.